Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:169
Name neuroendocrine tumor
Definition An endocrine gland cancer that has_material_basis_in neuroendocrine cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer neuroendocrine tumor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RB1 loss Sirolimus neuroendocrine tumor sensitive detail...
CDKN2A loss ZK 304709 neuroendocrine tumor sensitive detail...
Unknown unknown Surufatinib neuroendocrine tumor not applicable detail...
Unknown unknown Everolimus neuroendocrine tumor not applicable detail...
Unknown unknown Cixutumumab + Everolimus + Octreotide acetate neuroendocrine tumor not applicable detail...
BRAF V600E Dabrafenib + Trametinib neuroendocrine tumor predicted - sensitive detail...
BRAF V600E Trametinib + Vemurafenib neuroendocrine tumor predicted - sensitive detail...
Unknown unknown Axitinib neuroendocrine tumor not applicable detail...
Unknown unknown Everolimus + Pasireotide neuroendocrine tumor no benefit detail...
Unknown unknown Everolimus + Octreotide neuroendocrine tumor not applicable detail...
Unknown unknown Everolimus + Vorolanib neuroendocrine tumor not applicable detail...
Unknown unknown Pembrolizumab neuroendocrine tumor not applicable detail...
Unknown unknown CC-90011 neuroendocrine tumor not applicable detail...
Unknown unknown Toripalimab neuroendocrine tumor not applicable detail...
Unknown unknown DS6051b neuroendocrine tumor not applicable detail...
Unknown unknown Everolimus + Vatalanib neuroendocrine tumor not applicable detail...
Unknown unknown Onatasertib neuroendocrine tumor not applicable detail...
Unknown unknown Ipilimumab + Nivolumab neuroendocrine tumor not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00926640 Phase I Belinostat + Cisplatin + Etoposide A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA 3
NCT01466036 Phase II Cabozantinib Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Active, not recruiting USA 0
NCT01841736 Phase II Pazopanib Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting USA | CAN 0
NCT02063958 Phase I SNX-5422 Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors Completed USA 0
NCT02205515 Phase Ib/II Everolimus An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis Unknown status CAN 0
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed USA 0
NCT02259725 Phase II Regorafenib Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Completed USA 0
NCT02279433 Phase I DS6051b A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT02399215 Phase II Nintedanib Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting USA 0
NCT02402920 Phase I Carboplatin + Etoposide + Pembrolizumab Cisplatin Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer Recruiting USA 0
NCT02420691 Phase II Ribociclib LEE011 in Neuroendocrine Tumors of Foregut Origin Completed USA 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting USA 8
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Recruiting USA 0
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Active, not recruiting USA 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | CAN 19
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended USA 0
NCT02754297 Phase II lutetium Lu 177 dotatate Personalized PRRT of Neuroendocrine Tumors (P-PRRT) Recruiting CAN 0
NCT02795858 Phase II Octreotide + Ramucirumab A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Active, not recruiting USA 0
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn 0
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Active, not recruiting USA 1
NCT02939651 Phase II Pembrolizumab A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Active, not recruiting USA 0
NCT02955069 Phase II Spartalizumab Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Completed USA | CAN 11
NCT03014297 Phase I Everolimus + Fosbretabulin Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression Terminated USA 0
NCT03034200 Phase II ONC201 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting USA 0
NCT03070301 Phase II Everolimus + Ribociclib A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors Active, not recruiting USA 0
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Active, not recruiting USA 0
NCT03211988 Phase II Entinostat Entinostat Neuroendocrine (NE) Tumor Recruiting USA 0
NCT03289741 FDA approved Lanreotide acetate + Octreotide A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting USA 0
NCT03290079 Phase II Pembrolizumab Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas Recruiting USA 0
NCT03365791 Phase II LAG525 Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03375320 Phase III Cabozantinib Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting USA 0
NCT03411915 Phase I XmAb18087 A Study of XmAb18087 in Subjects With NET and GIST Recruiting USA 0
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Active, not recruiting USA 0
NCT03457948 Phase II Pembrolizumab Pembrolizumab + Yttrium-90 microsphere therapy Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases Recruiting USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting USA 0
NCT03950609 Phase II Everolimus + Lenvatinib Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors Recruiting USA 0
NCT04197310 Phase II Cabozantinib + Nivolumab Cabozantinib and Nivolumab for Carcinoid Tumors Recruiting USA 0
NCT04234568 Phase I lutetium Lu 177 dotatate + Triapine Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors Recruiting USA 0
NCT04412629 Phase II Cabozantinib Cabozantinib in High Grade Neuroendocrine Neoplasms Recruiting USA 0
NCT04614766 Phase Ib/II 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) Not yet recruiting USA 0